知镜 Cognispect · 医学文献与研究工作台

GLP-1 Receptor Agonist Use and Risk of Pain-Related Medical Encounters Among Patients with Comorbid Type 2 Diabetes and Opioid Use Disorder: A Target Trial Emulation Study.

Gain EP, Shrestha N, Eze JU, Wei YJ.
The journal of pain · 2026-11-12 · PMID 43020169

文献摘要

While GLP-1 receptor agonists (RAs) are postulated to alleviate pain, limited data exist to support the drugs' benefits in reducing pain-related medical encounters, particularly in patients with opioid use disorder (OUD), who have a high prevalence of pain. This study aims to examine the associations of GLP-1 RAs use with risk of emergency department (ED) visits or hospitalizations for pain among patients with comorbid type 2 diabetes (T2D) and OUD. We conducted a retrospective cohort study design in a target trial emulation framework using Merative MarketScan claims data between 2016 and 2023. Participants included adults between 18 and 64 years of age with a diagnosis of T2D and OUD who initiated GLP-1 RA or other second-line antidiabetic medication. Key outcomes included counts of incident pain-related ED visits, hospitalizations, or a composite outcome of either medical encounter, with a primary or secondary diagnosis coded for pain. Of 5842 eligible patients, those with use of GLP-1 RAs (vs. second-line antidiabetic medications) had a lower adjusted incident rate of pain-related ED visits (adjusted incidence rate ratio [aIRR]: 0.81; 95% CI: 0.69, 0.96, P=.01), pain-related hospitalizations (aIRR: 0.92; 95% CI: 0.68, 1.24, P=.56), although non-significant, and composite outcome of pain-related ED visit or hospitalization (aIRR: 0.83; 95% CI: 0.72, 0.97, P=.02). Initiation of GLP-1 RA therapy compared with second-line antidiabetic medication was associated with reduced risk of the composite outcome of pain-related ED visits or hospitalizations, indicating potential benefit of GLP-1 RA use for reducing pain-related medical encounters. Perspective In this cohort study, use of GLP1-1 RAs vs second-line drugs for T2D was associated with a lower risk of pain-related ED visits or hospitalizations among adults with comorbid T2D and OUD. GLP-1 RAs may be repurposed as a non-opioid pharmacological treatment for pain in patients with OUD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。